A Phase I Study to Evaluate BFPET as a Potential Myocardial Perfusion Imaging(MPI) Agent for PET

Coronary Artery Disease Clinical Trial

Official title:

A Phase I Study to Evaluate the Safety, Biodistribution and Radiation Dosimetry of BFPET as a Potential Myocardial Perfusion Imaging (MPI) Agent for PET

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00733460
• Other study ID #: BFPET P-01
• Status: Completed
• Phase: Phase 1
• First received: August 12, 2008
• Last updated: June 6, 2013
• Start date: March 2008
• Est. completion date: January 2012

Study information

• Verified date: June 2013
• Source: Fluoropharma, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Safety and dosimetry of BFPET™ will be evaluated in healthy volunteers and Coronary Artery Disease (CAD) patients , male or female and of age ranging between 20-80 years old.

Description:

Study Procedures:

Visit 1: Screening - Eligibility determination

Visit 2 (within 14 days post screening): Injection of BFPET™ and PET Imaging

Visit 3 (within 24-48 hours post dose): Follow-up Visit

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: January 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 20 Years to 80 Years

Eligibility

NORMAL HEALTHY VOLUNTEERS Inclusion Criteria

1. Subject must provide written informed consent prior to any study related procedures;

2. Subject must be = 20 and = 80 years of age;

3. Subject must have a serum creatinine within the investigational site's normal range.

4. Subject must have liver function tests < 1.5 times the investigational site's normal range.

5. Subject must have a hematocrit level within 5% of the investigational site's normal range.

Exclusion Criteria:

1. Any clinically significant acute or unstable physical or psychological disease based on medical history or screening physical examination;

2. Any clinically significant abnormality in the screening laboratory tests or ECG;

3. Any exposure to any investigational drugs within four (4) weeks prior to Visit 1;

4. Any exposure to investigational radiopharmaceuticals within four (4) weeks prior to the date of Visit 1;

5. Any new prescription medications within four (4) weeks of Visit 1;

6. Subject has a Positive (+) Serum Pregnancy Test, or the possibility of pregnancy cannot be ruled out prior to dosing or is breast-feeding. There are standard pregnancy procedures for use of radiopharmaceuticals in research at MGH.

7. Subject has experienced any allergic reaction to similar radiofluorinated compounds or agents.

CORONARY ARTERY DISEASE (CAD) SUBJECTS

Inclusion Criteria:

1. Subjects must provide written informed consent prior to any study related procedures;

2. Subjects must be = 20 and = 80 years of age;

3. Subjects must have history of CAD documented by an abnormal stress myocardial perfusion imaging (MPI) study and cardiac catheterization within 6 months of the BFPET studyExclusion Criteria

Exclusion Criteria:

1. Subject has a Positive (+) Serum and/or Urine Pregnancy Test or is lactating, or the possibility of pregnancy cannot be ruled out prior to dosing;

2. Any clinically significant acute or unstable physical or psychological disease judged by the investigators based on medical history or screening physical examination;

3. Coronary artery bypass graft (CABG) within 6 months;

4. Percutaneous coronary intervention (PCI), with stent placement within six months;

5. Blood pressure over 180/100;

6. Acute changes in ECG;

7. Recent (within 3 months) cardiac arrest, unstable angina, myocardial infarction, cerebro-vascular accident (CVA), any general anesthesia procedure, any surgical procedures;

8. Any implanted pacemaker or defibrillator use within the last three months;

9. Inability to remain in camera for approximately 60 minutes (Smokers and COPD are included as long as they can breath in PET camera and not taking O2 through nasal canula);

10. History of Diabetes Mellitus;

11. Serum creatinine > 2 mg/dL;

12. All cancer patients;

13. Body Mass Index (BMI) is over 35;

14. Any exposure to any investigational drugs or medical device within four (4) weeks prior to imaging study;

15. Any exposure to radiopharmaceuticals within four (4) weeks prior to the date of imaging study;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Intervention

Drug:
• BFPET

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Fluoropharma, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in blood pressure. Safety Biodistribution Radiation dosimetry	Change in vital signs, physical examination, ECG measured within 14 days of screening, immediate pre-dose, post-dose and 24-48 hours post-dose.; Change in 12-lead Electrocardiogram measured within 14 days of screening, immediate pre-dose, post-dose and 24-48 hours post-dose.; Change in 24-hour Holter (initiated 2 hours pre-dose, continuous for 24 hours, time stop recorded.; Change in dosimetry sampling (blood and urine)blood measured at time 0 (immediately following injection), 1,5, 15, 30, 60, 90 minutes.; Adverse event assessment immediate post dose, 24-48 hours and 7 days post-dose.	pre-dose, post-dose 0, 1, 5, 15, 30, 60 and 90 minutes, 2 hours, 24-48 hours post-dose and 7 days post-dose.	Yes
Secondary	Performance characteristics of BFPET as a PET tracer for myocardial imaging.	Whole body imaging measures radiation dosimetry at rest and under pharmacologic stress	30, 60, 120, and 240 seconds.	No

External Links

•   Click here for more information on BFPET P-01